Sound View Wealth Advisors Group LLC raised its stake in Danaher Co. (NYSE:DHR – Free Report) by 3.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,739 shares of the conglomerate’s stock after buying an additional 52 shares during the period. Sound View Wealth Advisors Group LLC’s holdings in Danaher were worth $399,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in the stock. FMR LLC boosted its holdings in Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after acquiring an additional 3,217,631 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Danaher in the 4th quarter valued at $391,172,000. Van ECK Associates Corp increased its position in shares of Danaher by 6,862.7% during the fourth quarter. Van ECK Associates Corp now owns 929,868 shares of the conglomerate’s stock worth $213,452,000 after buying an additional 916,513 shares during the period. Proficio Capital Partners LLC raised its stake in Danaher by 29,287.7% during the fourth quarter. Proficio Capital Partners LLC now owns 588,929 shares of the conglomerate’s stock worth $135,189,000 after buying an additional 586,925 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its holdings in Danaher by 17.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after buying an additional 535,254 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.
Insider Transactions at Danaher
In related news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 11.10% of the company’s stock.
Analyst Ratings Changes
View Our Latest Stock Report on Danaher
Danaher Trading Down 3.3 %
Shares of Danaher stock opened at $205.02 on Tuesday. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The stock has a fifty day simple moving average of $222.02 and a 200 day simple moving average of $242.18. Danaher Co. has a 12-month low of $196.80 and a 12-month high of $281.70. The company has a market capitalization of $146.53 billion, a P/E ratio of 38.83, a price-to-earnings-growth ratio of 2.66 and a beta of 0.82.
Danaher (NYSE:DHR – Get Free Report) last posted its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period last year, the business posted $2.09 earnings per share. On average, sell-side analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current fiscal year.
Danaher Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a dividend of $0.32 per share. The ex-dividend date is Friday, March 28th. This represents a $1.28 annualized dividend and a dividend yield of 0.62%. This is a boost from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio (DPR) is currently 24.24%.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
- Five stocks we like better than Danaher
- Following Congress Stock Trades
- How to Protect Your Portfolio When Inflation Is Rising
- How to Use the MarketBeat Dividend Calculator
- 3 Tech Stocks Defying Sector Weakness and Thriving in 2025
- 5 Top Rated Dividend Stocks to Consider
- Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.